相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BiTE secretion from in situ-programmed myeloid cells results in tumor-retained pharmacology
S. Hao et al.
JOURNAL OF CONTROLLED RELEASE (2022)
Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer
Ilkka Liikanen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer
James H. A. Clubb et al.
FRONTIERS IN IMMUNOLOGY (2022)
Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression
Tatiana Kudling et al.
ONCOIMMUNOLOGY (2022)
Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes
Sadia Zafar et al.
CANCER GENE THERAPY (2021)
Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer
Po-Hao Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
Riikka Havunen et al.
CELLS (2021)
Current development in adenoviral vectors for cancer immunotherapy
Greyson Willis Grossman Biegert et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control
Dafne C. A. Quixabeira et al.
FRONTIERS IN IMMUNOLOGY (2021)
Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition
Oladapo O. Yeku et al.
FRONTIERS IN IMMUNOLOGY (2021)
MUC1: Structure, Function, and Clinic Application in Epithelial Cancers
Wenqing Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Efficacy and safety of MUC1 targeted CIK cells for the treatment of advanced liver cancer.
Yin Ying Lu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Oncolytic Adenovirus: Prospects for Cancer Immunotherapy
Yaqi Zhao et al.
FRONTIERS IN MICROBIOLOGY (2021)
Summary of a workshop on preclinical and translational safety assessment of CD3 bispecifics
Cris Kamperschroer et al.
JOURNAL OF IMMUNOTOXICOLOGY (2020)
Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor
Lukasz Kuryk et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors
Caroline E. Porter et al.
MOLECULAR THERAPY (2020)
The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types
Hermann Einsele et al.
CANCER (2020)
TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling
Camilla Heinio et al.
CELLS (2020)
Perspective: Designing T-Cell Engagers With Better Therapeutic Windows
Omid Vafa et al.
FRONTIERS IN ONCOLOGY (2020)
T cell-engaging therapies - BiTEs and beyond
Maria-Elisabeth Goebeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Oncolytic Viruses and the Immune System: The Dynamic Duo
Ana Lemos de Matos et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
Victor Cervera-Carrascon et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy
Lobke C. M. Hensen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
Victor Cervera-Carrascon et al.
ONCOIMMUNOLOGY (2020)
Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
Victor Cervera-Carrascon et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?
Stefan Mereiter et al.
CANCER CELL (2019)
Latest developments in MUC1 immunotherapy
Joyce Taylor-Papadimitriou et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2018)
Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors
Stijn J. H. Waaijer et al.
CLINICAL CANCER RESEARCH (2018)
CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy
Sadia Zafar et al.
ONCOIMMUNOLOGY (2018)
Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2
Feng Cai et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Bispecific antibodies for viral immunotherapy
Elisabeth K. Nyakatura et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy
Riikka Havunen et al.
MOLECULAR THERAPY-ONCOLYTICS (2017)
Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment
T. Yuraszeck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy
Carlos Alberto Fajardo et al.
CANCER RESEARCH (2017)
Harnessing T cells to fight cancer with BiTE® antibody constructs - past developments and future directions
Matthias Klinger et al.
IMMUNOLOGICAL REVIEWS (2016)
Bispecific antibodies
Roland E. Kontermann et al.
DRUG DISCOVERY TODAY (2015)
Are BiTEs the missing link in cancer therapy?
Carter M. Suryadevara et al.
ONCOIMMUNOLOGY (2015)
Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma
Mikko Siurala et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy
Feng Yu et al.
MOLECULAR THERAPY (2014)
Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling
R. Kamekura et al.
ONCOGENE (2014)
Desmoglein 2 Depletion Leads to Increased Migration and Upregulation of the Chemoattractant Secretoneurin in Melanoma Cells
Wiebke K. Peitsch et al.
PLOS ONE (2014)
Characterization of Desmoglein Expression in the Normal Prostatic Gland. Desmoglein 2 Is an Independent Prognostic Factor for Aggressive Prostate Cancer
Alison G. Barber et al.
PLOS ONE (2014)
The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression
Junli Deng et al.
CANCER AND METASTASIS REVIEWS (2013)
EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
Michele Cioffi et al.
CLINICAL CANCER RESEARCH (2012)
Epithelial cell polarity and tumorigenesis: new perspectives for cancer detection and treatment
Danila Coradini et al.
ACTA PHARMACOLOGICA SINICA (2011)
A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses
J. J. Rojas et al.
GENE THERAPY (2009)
Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor
Scott Wilkie et al.
JOURNAL OF IMMUNOLOGY (2008)
Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma
Masakazu Yashiro et al.
EUROPEAN JOURNAL OF CANCER (2006)
Oncolytic adenoviruses - selective retargeting to tumor cells
JM Mathis et al.
ONCOGENE (2005)
MUC1 as a target antigen for cancer immunotherapy
B Acres et al.
EXPERT REVIEW OF VACCINES (2005)
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus
A Kanerva et al.
MOLECULAR THERAPY (2003)
分享论文
